Creative Biolabs is a first-class service provider focused on antibody development and antibody functional assays. CTLA-4 blockade assay is an effective method which enables to measure the activity of antibody targeting CTLA-4 and to explore the mechanism of action (MOA) of biologics designed to block CTLA-4. Aided by experienced experts and advanced technology platforms, we are confident in providing first-in-class CTLA-4 blockade assays.
Cytotoxic T-lymphocyte associated protein 4 (CTLA-4), also known as CD152, is an immune inhibitory receptor expressed on CD4+ T cells that competitively binds CD80 (B7.1) and CD86 (B7.2) to downregulate T cell activity. CTLA-4 has been identified as the counterpart of the co-stimulatory B7-CD28 pathway. It highly expressed on the surface of T cells binds to B7 with higher avidity than CD28, and thus outcompetes the positive co-stimulatory signal from CD28. Furthermore, CTLA-4 binding with its ligands, CD80 (B7-1) or CD86 (B7-2) on an adjacent antigen presenting cell (APC) can inhibit CD28 co-stimulation of T cell activation, cell proliferation, and cytokine production. Indeed, cross-linking of CTLA-4 molecules on the cell surface leads to a decreased T cell proliferation and IL-2 production. As thus, CTLA-4 plays an essential role in regulating immune responses to tumor antigens and autoantigens. It has been shown as a key target in drug discovery for cancer and blocking it can reduce tumor size. With the success of CTLA-4 immunotherapy drug ipilimumab (marketed as YERVOY for metastatic melanoma), other new therapeutic antibodies and Fc fusion proteins blocking the CTLA-4/CD80 and CD86 interaction have been shown as promising therapeutic drugs for the treatment of a variety of cancers.
Fig.1 Cellular expression of CTLA-4 and Foxp3. (Walker, 2013)
CTLA-4 blockade assay is a bioluminescent cell-based assay that overcomes the limitations of current methods (such as complex assay protocols, unqualified assay reagents, and independent of donor primary cells). This test can be used to measure the potency and stability of antibodies and other biologics targeting CTLA-4. Besides, it is also used to describe the MOA of biologics designed to block the interaction of CTLA-4 with its ligands, CD80 and CD86. Creative Biolabs has accumulated extensive experience in antibody functional assays. We are proud to offer high-quality CTLA-4 blockade assay services for both antibodies and other biologics to global customers. Our services are characterized by:
With the years of experience in the field of antibody functional assays, Creative Biolabs is specialized in offering high-quality functional assays for antibodies targeting CTLA-4. We are dedicated to providing reliable results for your project, thereby facilitating the clinical application transformation of your antibody drugs. For more detailed information, please feel free to contact us or directly sent us an inquiry.
Reference
For Research Use Only.
